Alopecia in Gender-Diverse Patients: Beyond Cosmetics to Clinical Significance

For transgender and gender-diverse individuals, androgenetic alopecia can represent a deeply distressing intersection of medical condition and identity—one that clinicians have long managed without dedicated evidence to guide them.

A narrative review published in Dermatology and Therapy synthesized available data on the epidemiology, pathophysiology, clinical presentation, and management of androgenetic alopecia (AGA) in transgender and gender-diverse (TGD) individuals, offering a practical framework for clinicians who may have limited experience treating this population. Researchers from dermatology and endocrinology departments across Spain searched PubMed, Embase, Cochrane, and ClinicalTrials.gov from database inception through January 1, 2026, ultimately identifying 29 relevant studies focused specifically on hair loss in TGD populations.

Elevated AGA Rates Linked to Masculinizing Hormone Therapy

The burden of AGA was found to fall disproportionately on transgender men receiving testosterone therapy. Published data showed AGA rates between 32.1% and 63.3% in this group, with approximately 31% developing moderate to severe disease.² A large retrospective cohort study cited in the review found that transmasculine individuals experienced AGA at 2.5 times the rate of cisgender women.³ Among transgender women, incidence of AGA was comparable to cisgender men and nearly double that of cisgender women, with an adjusted incidence rate ratio of 1.91.

Androgen Timing Shapes Onset and Hair Loss Patterns

The biological mechanism of AGA in TGD individuals mirrors that seen in cisgender populations—follicular sensitivity to androgens driving progressive miniaturization—but the timing of hormonal intervention introduces meaningful clinical distinctions. In transgender men, AGA most commonly emerged after testosterone initiation, with a typical expected onset of 12 months after starting therapy. The highest incidence of AGA diagnosis occurred in the fourth year of masculinizing therapy, with a median diagnostic lag of 2.8 years. Notably, hair loss sometimes preceded other androgen-dependent changes such as facial and body hair growth, reflecting differential androgen sensitivity across pilosebaceous units.

For transgender women, AGA predominantly reflected prior androgen exposure, and feminizing hormone therapy was more likely to stabilize progression than produce substantial regrowth—though case reports documented improvements with estradiol and spironolactone combination therapy.

Oral Minoxidil Identified as Cornerstone Therapy Across TGD Populations

Two small retrospective cohorts provided direct evidence on oral minoxidil in TGD individuals. One study of 27 patients reported improvement in 100% of transgender women (median dose, 1.5 mg daily) and 80% of transgender men (median dose, 5 mg daily). A separate cohort found improvement across all patients studied at median doses of 2.5 mg for transgender men and 1.88 mg for transgender women.

Of clinical interest, higher oral minoxidil doses of 7.5 mg to 10 mg daily in transgender men were well tolerated and correlated with meaningful increases in beard and body hair—outcomes that carried independent significance for gender affirmation beyond scalp density alone. The authors concluded that dosing decisions should be driven by therapeutic goals rather than assigned sex at birth.

5-Alpha Reductase Inhibitors Carry Unique Risks and Reassurances

For transgender men, the addition of dutasteride 0.5 mg or finasteride 1 mg to oral minoxidil was recommended. Historical concerns about 5-alpha reductase inhibitor (5-ARI) use interfering with masculinization were partially addressed by a 453-patient retrospective trial of cisgender men, in which 96.9% experienced no change in beard thickness on either agent. However, clinicians were advised to monitor for resumption of menstruation—documented in 2 of 3 transgender men in a recent case series—and to counsel individuals about fertility preservation and the need for contraception in those with retained gonads.

For transgender women, spironolactone at 100 to 200 mg daily was identified as a preferred first-line antiandrogen, serving dual roles in AGA treatment and feminizing hormone therapy.

Evidence Gaps Limit Clinical Certainty

The authors acknowledged that many recommendations rested on evidence extrapolated from cisgender populations or on expert clinical opinion, given the scarcity of high-quality TGD-specific studies. The narrative methodology also precluded formal evidence grading.

The authors underscored that effective management demanded "an individualized, goal-oriented, and gender-affirming approach," and called for prospective studies to establish evidence-based treatment algorithms and define long-term outcomes in TGD individuals.

References

1. Ramos-Rodriguez D, Sancez-Baez D, Cabrera-Garcia P, et al. Characterization and management of androgenetic alopecia in transgender and gender-diverse individuals: a narrative review. Dermatol Ther (Heidelb). 2026;16(5):2343-2362. doi:10.1007/s13555-026-01735-9

2. Thoreson N, Grasso C, Potter J, King DS, Peebles JK, Dommasch ED. Incidence and factors associated with androgenetic alopecia among transgender and gender-diverse patients treated with masculinizing hormone therapy. JAMA Dermatol. 2021;157(3):348-349. doi:10.1001/jamadermatol.2020.5475

3. Gao JL, Sanz J, Tan N, King DS, Modest AM, Dommasch ED. Androgenetic alopecia incidence in transgender and gender diverse populations: a retrospective comparative cohort study. J Am Acad Dermatol. 2023;89(3):504-510. doi:10.1016/j.jaad.2023.01.037